Kanada - angličtina - Health Canada

bristol-myers squibb canada - econazole nitrate - cream - 1% - econazole nitrate 1% - azoles

Spojené štáty - angličtina - NLM (National Library of Medicine)

county line pharmaceuticals, llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. it should not be used

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metronidazole, quantity: 7.5 mg/g - gel - excipient ingredients: carbomer 974p; propylene glycol; sodium hydroxide; disodium edetate; propyl hydroxybenzoate; methyl hydroxybenzoate; purified water - zidoval vaginal gel 0.75% is indicated in the treatment of symptomatic bacterial vaginosis (formerly referred to as haemophilus vaginalis vaginitis, gardnerella vaginalis vaginitis, non-specific vaginitis, corynebacterium vaginale vaginitis or anaerobic vaginosis). note: for purpose of this indicated, a clincial diagnosis of bacterial vaginosis is usually defined by the presence of at least three of the following four criteria: a) vaginal discharge ph of greater than 4.5, b) a vaginal discharge emitting a "fishy" amine odour when mixed with a 10% koh solution, c) a vaginal discharge containing clue cells on wet mount microscopy examination, d) a gram stain consistent with a diagnosis of bacterial vaginosis (lactobacillus morphotype absent of markedly decreased, gardnerella morphotype predominant flora, white blood cells absent or few, mobiluncus morphotype may or may not be present). a diagnosis of bacterial vaginosis requires that other pathogens which may be associated with genital infection, such as trichomonas vaginalis, candida albicans, chlamydia trachomatis and neisseria gonorrhoeae, should be ruled out be appropriate laboratory means.

Spojené štáty - angličtina - NLM (National Library of Medicine)

alvogen inc. - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. it should not be used

Južná Afrika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

alliance pharma (pty) ltd - tablet - see ingredients - each tablet contains sulfathiazole 500 mg

Južná Afrika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

the premier pharmaceutical co ltd - tablet - each tablet contains sulfadiazine 185 mg sulfathiazole 185 mg sulphamerazine 130 mg

Južná Afrika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

genpharm pharmaceuticals (1993) (pty) ltd - tablet - see ingredients - each tablet contains sulfadiazine 200 mg sulfadimidine 100 mg sulfathiazole 200 mg

Južná Afrika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

allied drug company (pty) ltd - liquid - each 5 ml contains sulfadiazine 185 mg sulfathiazole 185 mg sulphamerazine 130 mg